Gemcitabine-O-Si(di-iso)-O-Mc |
| Catalog No.GC60870 |
Gemcitabine-O-Si(di-iso)-O-Mc est un conjugué médicament-lieur pour l'ADC avec une puissante activité antitumorale en utilisant la Gemcitabine (un antimétabolite analogue de nucléoside pyrimidique et un agent antinéoplasique;), lié via le lieur ADC.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Gemcitabine-O-Si(di-iso)-O-Mc is a drug-linker conjugate for ADC with potent antitumor activity by using Gemcitabine (a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent;), linked via the ADC linker[1].
Antibody drug conjugates (ADC) couple therapeutic monoclonal antibodies (mAb) with potent toxins through a linker that is stable within systemic circulation, but cleaves within the target cells[1].
[1]. Mathew C. Finniss, et al. A versatile acid-labile linker for antibody-drug conjugate. MedChemComm, Issue 9, 2014.
Average Rating: 5 (Based on Reviews and 21 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *